NCT05421663

A Study of JNJ-90014496 in Participants With B-Cell Non-Hodgkin Lymphoma

A Phase 1b/2, Multicenter, Open-label, Study of JNJ-90014496, an Autologous CD19/CD20 Bi-specific CAR-T Cell Therapy in Adult Participants With B-cell Non-Hodgkin Lymphoma

• Status: Recruiting
• Phase: Phase 1 / Phase 2
• Study type: Interventional
• Enrollment: 439 (estimated)
• Sponsor: Janssen Research & Development, LLC · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

This is a Phase 1b/2, multicenter, open-label, study of prizloncabtagene autoleucel (prizlo-cel), an autologous dual targeting chimeric antigen receptor (CAR) T-cell therapy targeting both cluster of differentiation (CD) CD20 and CD19, for the treatment of adult participants with relapsed or refractory (r/r) B-Cell non-Hodgkin lymphoma (B-NHL) or frontline high-risk diffuse large B-cell lymphoma (DLBCL).

Conditions

• Lymphoma, Non-Hodgkin
• Lymphoma, B-Cell
• Lymphoma, Large B-Cell, Diffuse

Interventions

Type	Name	Description
BIOLOGICAL	Prizloncabtagene autoleucel (Prizlo-Cel)	Prizlo-Cel, an autologous dual targeting chimeric antigen receptor (CAR) - T cell therapy targeting Cluster of differentiation (CD)20 and CD19.

Timeline

• Start date: 2022-08-12
• Primary completion: 2028-12-29
• Completion: 2029-03-29
• First posted: 2022-06-16
• Last updated: 2026-04-13

Locations

32 sites across 8 countries: United States, Australia, Canada, Denmark, Netherlands, South Korea, Spain, United Kingdom

Regulatory

• FDA-regulated drug study